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THE USE OF DNA FLOW CYTOMETRY AS A PROGNOSTIC INDICATOR 
AFTER LOCAL RECURRENCE IN CONSERVATIVELY TREATED CLINICAL 
STAGE I AND II BREAST CANCERS. Margaret M. Toth, Stuart D. Flynn, and 
Bruce G. Haffty. Department of Therapeutic Radiology, Yale University, School of 
Medicine, New Haven, CT. 
Abstract 
Over the past decade, breast conserving surgery with primary radiotherapy has 
been frequently employed as an option for the treatment of early breast cancer. With 
increasing follow-up, it is clear conservatively treated patients have a long-term risk for 
local recurrence. To date, prognostic indicators following recurrence are limited to 
clinical and pathological observations. No objective prognostic parameters have been 
established. 
The purpose of the research summarized in this thesis was to determine whether 
DNA flow cytometry is a useful indicator of prognosis in patients who have suffered 
local recurrence following conservative treatment. Archival breast tissue specimens 
from tumor recurrences were obtained from 38 of the 50 women in the Yale-New 
Haven Hospital series who suffered local failure following conservative treatment. 
Median follow-up after recurrence was 5.06 years. 
DNA flow cytometric measurements of DNA-ploidy and S-phase fraction were 
performed on all available samples. 62% of patients had DNA-diploid recurrent 
tumors. DNA-ploidy was predictive of both overall and disease-free survival at five 
years (p=0.015 and p=0.028). S-phase fraction proved to be a highly significant 
predictor of prognosis. 35% of patients had low SPF tumors (SPF < 12). The 
probability of disease-free survival five-years post-recurrence was 100% for the low 
SPF tumor patients and 32% for patients with high SPF tumors (p=0.00005). DNA- 
ploidy and S-phase fraction were combined to define favorable and unfavorable flow 
profiles (favorable = DNA-diploid, SPF < 12). Actuarial disease-free survival five- 
years post-recurrence was 100% for patients with a favorable flow profile and 36% for 
patients with an unfavorable flow profile (p=0.0002). This data suggests DNA flow 
cytometric measurements at relapse strongly correlate with outcome for patients 
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THE USE OF DNA FLOW CYTOMETRY AS A PROGNOSTIC 
INDICATOR AFTER LOCAL RECURRENCE IN CONSERVATIVELY 
TREATED CLINICAL STAGE I AND II BREAST CANCERS. 
Introduction 
Breast cancer is the most common malignancy among western women with 
124,000 new cases reported each year in the United States.1 Although each American 
woman has a one in ten risk of developing the disease, early detection of breast lesions 
with self-examination and screening mammography appear to have increased the 
number of women for whom cure is possible. Currently, a number of local treatment 
options, ranging from modified radical mastectomy to breast conserving surgery with 
radiation therapy, are available. In addition, systemic chemotherapy can be added to 
delay, if not prevent, distant metastases. Rationale and justification for the use of 
conservative treatment for early stage breast cancer can be derived from numerous 
retrospective as well as prospective studies.211 
Patients whose breast cancer has been conservatively treated have a protracted 
risk for local recurrence. Following local recurrence, salvage mastectomy can be 
performed offering 59-84% survival at five years.1215 Even though many qualitative 

clinical and pathological variables have been associated with prognosis at the time of 
local recurrence, quantitative variables are lacking.16 20 DNA flow cytometric (DNA- 
FC) parameters successfully predict prognosis for patients with primary breast 
cancer.2130 The research summarized in this thesis investigates the prognostic value 
of DNA-FC for women who have experienced local failure following conservative 
treatment of stage I and II breast cancers. 
TREA TMENT OPTIONS FOR EARL Y BREAST CANCER 
Since Roman times, early breast cancer has been considered a local problem 
amenable to surgical treatment. Until recently, the Halsted radical mastectomy, 
developed by William Stewart Halsted at the Johns Hopkins Hospital during the 
1890’s, has remained the standard treatment for early breast cancer in the United States. 
This procedure assumes breast cancer is initially a local disease, and includes surgical 
removal of the breast, pectoral fascia, pectoralis major and minor muscles and in most 
cases complete axillary dissection. The modified radical mastectomy is now the most 
commonly applied technique for breast amputation. In addition to removal of the 
cancerous breast, the underlying pectoralis minor muscle, pectoralis fascia and in most 
cases draining axillary nodes are removed. 
With publication in the mid 1960’s of the first reports of primary breast 
irradiation, a new era in breast cancer treatment began.31'34 These early reports of 
conservative treatment with limited surgery and primary irradiation were limited to 
patients who had either refused a radical mastectomy, were elderly or too ill for surgery 
or had locally advanced disease unsuitable for mastectomy. The reports were 
2 

noteworthy as they demonstrated long term survival was possible for at least some 
patients treated with conservative surgery and primary radiotherapy This led to 
experimental trials of conservative treatment and subsequently several definitive 
prospective studies in the United States and Europe which have established the efficacy 
of conservational surgery with radiation therapy (CS+p°RT) for the treatment of early 
breast cancer. 
EVIDENCE JUSTIFYING THE USE OF CONSERVATIVE TREATMENT FOR 
EARL Y BREAST CANCER 
During the last decade, CS+p°RT has been used increasingly for the treatment 
of early stage breast cancer. This treatment involves excision of the malignant breast 
lesion, preserving the breast’s cosmetic appearance, and departs from the historical 
perspective of breast cancer controlled by ablative local surgery. Such removal of the 
lesion is followed by definitive irradiation of the involved breast with or without 
irradiation of the regional axillary, internal mammary and supraclavicular lymph nodes. 
The first studies of conservative treatment for early stage breast cancer were 
necessarily retrospective. The largest of these are summarized in table 1. Drawing 
conclusions from these studies is hindered by differences in patient selection, mode of 
staging, surgical technique, dose of radiation and statistical methods employed. Yet, all 
demonstrate disease-free and overall survival following CS+p°RT similar to that 
achieved with mastectomy.2 
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The Yale-New Haven Hospital experience is typical of the retrospective data 
supporting the use of CS+p°RT as an option for the treatment of early stage breast 
cancer.5 This series included 433 women treated with CS+p°RT at the Yale-New 
Haven Hospital between 1962-1984 of which 70% were clinically stage I and 30% 
were stage II. All patients were followed for a minimum of five years. 
The conservational surgical technique was limited to excision of local tumor 
with a rim of grossly normal tissue, without a specific requirement for microscopically 
free surgical margins. Axillary dissections were not routinely performed. Radiation 
therapy was defined by tangential fields to the breast with an electron boost to the tumor 
bed to a total median tumor dose of 6400 cGy. The regional nodes were treated in the 
majority of patients by separate internal mammary and supraclavicular/axillary portals 
to a total median dose of 4600 cGy. Most patients did not receive adjuvant systemic 
therapy. 
Five-year actuarial survival was 86%. The actuarial breast recurrence rate at 
five years was 8% of which 82% were salvaged with mastectomy or repeated wedge 
resection. The five-year actuarial survival following breast only recurrence was 59% 
and the five-year disease-free survival was 65%. 
The results of the Yale experience together with those of the institutions listed in 
table 1 demonstrated long term survival following CS+p°RT was comparable to that 
achieved with more traditional radical therapy. The retrospective design of these 
studies precludes an absolute conclusion but justified randomized prospective trials 
comparing the two types of therapy. 
4 

In order to establish CS+p°RT as an alternative treatment for early breast 
cancer, five well-designed randomized prospective trials, as summarized in table 2, 
were undertaken.3'4 6 35 36 Of these, the National Surgical Adjuvant Breast Project 
Protocol B-06 (NSABP B-06) is most representative.6 1,843 patients with clinical 
stage I and stage II breast cancer enrolled between April 1976 and January 1984 and 
were randomly assigned to one of three groups receiving treatment with either 
mastectomy alone, or conservational surgery with or without primary radiotherapy. All 
patients underwent axillary dissection. Those with positive nodes received adjuvant 
chemotherapy. Radiotherapy was delivered to the breast only to a total dose of 5,000- 
5,300 cGy, without a boost to the tumor site. 
Among node negative patients treated with mastectomy, five-year disease-free 
survival was 71.9% compared to 81.4% for the CS+p°RT group. Overall, survival 
was 81.7% in the mastectomy group and 90.7% in the CS+p°RT group. The five-year 
actuarial recurrence rate for patients treated with CS+p°RT was 7% compared to a rate 
of 32% in patients treated with conservational surgery alone. Life table estimates 
indicated treatment by conservational surgery, with or without breast irradiation, 
resulted in disease-free, distant disease-free and overall survival at five years that did 
not statistically differ from that of patients treated with traditional mastectomy. This 
study did, however, show a trend towards a longer disease-free and overall survival for 
patients treated with CS+p°RT. 
Several studies have investigated the cosmetic sequelae of conservative 
treatment. Delouche, at the Centre de Charlebourg in Paris, examined 330 patients 
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conservatively treated for clinical stage I and II breast cancer and followed for a 
minimum of two years.7 In 37.6% of these patients, the treated breast appeared to be 
essentially identical to the untreated breast. In 39.1%, minor sequelae of treatment 
were apparent, including breast asymmetry, modest subcutaneous induration or skin 
changes due to radiotherapy. More marked changes were noted in 16.7%, 
corresponding to significant deformation of the treated breast and 6.7% of the patients 
had unacceptable results, representing either a cosmetically unsightly or painful 
shrunken breast. Similarly, follow-up of five years for 239 conservatively treated 
patients was obtained by the Joint Center for Radiation Therapy (JCRT) at Harvard 
University.37 Overall cosmetic results were found to deteriorate for the first three years 
following therapy, after which they stabilized. At five years overall cosmetic results 
were judged as excellent (little or no change) in 77% of patients, good (minimal, but 
identifiable changes) in 9%, fair (significant results of radiation therapy noted) in 9%, 
and poor (severe normal tissue sequelae) in 5%. Poor cosmesis was related to extent of 
surgery, with patients undergoing more extensive excisions having poorer results and 
total dose of radiation, with a total dose greater than 5,000 cGy being associated with 
greater degrees of fibrosis and retraction. 
Additional complications of conservative treatment are those experienced during 
primary irradiation of the treated breast. Acute complications include fatigue, irritation 
and erythema of the skin. These are self-limited, usually resolving within several 
weeks of treatment. Significant long term complications are unusual. The JCRT 
reports rib fractures as the most common (5%) followed by cosmetically significant arm 




In 1990, with strong support for the use of conservative treatment for early 
breast cancer, a panel of experts convened to provide consensus recommendations for 
conservative surgical treatment techniques and patient selection criterion.38 The major 
criterion for patient selection is feasibility of resecting the primary tumor without major 
cosmetic deformity. Patients not considered appropriate candidates include those with 
two widely separated primary tumors in the same breast and patients whose 
mammography reveals diffuse micro-calcifications. Surgical removal of the tumor 
should be performed to achieve grossly negative margins of resection with verification 
of microscopically free margins determined on permanent histologic sections after 
inking of the specimen’s borders. Further resection in the case of positive margins is 
recommended. Axillary dissection, (levels 1-2), provides valuable prognostic 
information for patients with primary breast cancer and may be routinely employed. It 
is recommended the entire breast be irradiated to a total dose of 4,500-5,000 cGy, with 
a boost delivered to the region of the tumor to doses of 1,000-1,500 cGy. It is noted, 
higher doses of radiation may result in an unacceptable degree of fibrosis and 
retraction. Future research aimed at refining existing prognostic factors and identifying 
subgroups most likely to benefit from further adjuvant therapy is encouraged. 
LOCAL RECURRENCE IN CONSER VA TIVEL Y TREA TED PA TIENTS 
Having established CS+p°RT as an option for the treatment of early breast 
cancer, data accumulated from retrospective and prospective studies was analyzed to 
define the natural history of breast cancer treated with conservative therapy. One initial 
conclusion derived from such analyses was that local recurrence in conservatively 
treated patients occurred over a protracted time interval. Unlike patients treated with 
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mastectomy, most of whom recur within three years, conservatively treated patients are 
at constant low risk of recurrence for many years following their initial treatment.39 A 
collaborative study, conducted at the Princess Margaret Hospital, the Institut Curie and 
the Marseilles Cancer Institute, demonstrated a constant risk of local recurrence over a 
fourteen year period.12 In the Yale series, the breast recurrence rate at five years was 
8%, consistent with the 1-2% annual risk of recurrence reported by most institutions.5 
Table 3 summarizes the long risk periods reported for conservatively treated patients. 
The continued risk of local recurrence in conservatively treated patients 
reinforces the need to emphasize rigorous follow-up, as patients treated with breast 
preserving therapy retain breast tissue at risk for developing a second primary tumor or 
a recurrence of the original tumor from residual malignant cells which survived the 
initial treatment. 
Since the majority of local recurrences in conservatively treated patients occur at 
or near the primary site, most are probably recurrences of the primary tumor. 67% of 
the recurrences in the Yale series occurred at the same site, defined as at or near the 
original primary site, while 33% were observed elsewhere in the breast.5 Analysis of 
recurrences in the JCRT series, after four and a half years of follow-up, revealed 57% 
occurring directly at the site of the primary, 33% occurring at the edge of the boosted 
volume and 10% occurring elsewhere in the breast.40 Similarly, the Marseille group 
reported 79% of their recurrences occurring in the vicinity of the primary tumor bed but 
noted that with longer times to recurrence, an increasing percentage were found 
elsewhere in the breast.41 Based on such observations, they have suggested that 
tumors recurring late should be considered second primary tumors. 
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Pathological examination of recurrences undertaken by the JCRT and the 
NSABP B-06 project, noted identical or similar histologies among nearly all primaries 
and local recurrences found at or near the original site.17 42 Review of primary and 
recurrence material from the 24 local recurrences treated at Gustave-Roussy revealed in 
all cases unchanged histological subtype and little or no change in tumor grade.13 
FACTORS PREDICTING LOCAL RECURRENCE IN CONSERVATIVELY 
TREA TED PA TIE NTS 
Extensive efforts have been made to identify factors which can predict which 
patients will have a high risk of local recurrence following conservative treatment.8- 
11,13.41,43-46 To date, these predictive factors fall into two categories: factors related to 
tumor burden and factors related to intrinsic tumor biology. 
Conservational therapy aims to preserve the cosmetic appearance of the 
cancerous breast; therefore, it is conceivable that micro-foci of malignant cells remain in 
the affected breast after tumor excision. In this case, the primary radiotherapy 
employed after excision should help eliminate the remaining tumor cells. Extent of 
initial conservational surgery and degree of intra-ductal carcinoma in the primary, as 
well as the dosage and timing of primary irradiation and other clinical and pathological 
factors have been reported as prognostic of local recurrence. 
Patients in the JCRT series having a less-than-excisional biopsy of their primary 
suffered a higher percentage of local recurrence than those undergoing complete 
excisional biopsy (35% vs 7%).40 When primary tissue from patients suffering local 
failure in the JCRT series was histologically analyzed, tumors noted to have an 
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extensive intra-ductal component, (EIC), (considered present when intra-ductal 
carcinoma occupied 25% or more of the area encompassed by the infiltrating tumor and 
was present in random sections of grossly unremarkable breast tissue or clearly 
extended beyond the infiltrating edge of the tumor into surrounding breast tissue) were 
associated with a substantially increased risk for local failure after ten-years of follow¬ 
up. Patients without EIC experienced a 3% failure rate at ten-years compared to a 35% 
failure rate for those with EIC.45 However, several groups, including Yale and the 
Institut Gustave-Roussy, have failed to demonstrate a similar predictive value for EIC, 
while the Institut Curie found EIC slightly correlated with increased local recurrence but 
also associated with better survival.13 37 
Patients experiencing local recurrences in the Institut Gustave-Roussy series 
were analyzed for thirty variables related to breast relapse.13 Two of the three factors 
correlated with local recurrence were duration of radiation treatment and time interval 
between tumor excision and initiation of radiotherapy. Patients whose treatments were 
delivered in less than six weeks and those who experienced a delay of more than seven 
weeks between initial biopsy and radiotherapy had a greater risk of local failure. 
Analysis of JCRT data revealed the risk of recurrence at the site of the primary 
was related to the dose of radiation given to the primary site.40 Recurrences at the 
original site were rare in patients receiving doses greater that 6000 cGy. Thus, as 
dosage of radiation increases and interval to treatment following initial biopsy is 
shortened, the tumor burden remaining after surgery is presumed to be more effectively 
eliminated and risk of local recurrence diminished. 
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The Yale series demonstrated patients with positive axillary nodes had a lower 
rate of local recurrence.48 These patients also tended to be younger, have larger 
primaries and more aggressive tumor histologies. Given these negative prognostic 
factors, one would have expected these patients to have a higher local recurrence rate. 
Instead, they fared better than their node-negative counterparts. It is speculated this 
may be related to the fact that 88% of node-positive patients in the Yale series received 
adjuvant systemic therapy in contrast to 8% of the node-negative patients. Here again, 
the use of adjuvant therapy, in this case chemical and/or hormonal, theoretically 
eliminated the residual tumor burden following conservative therapy, thereby reducing 
the risk of local recurrence. 
Factors related to tumor aggressiveness have also been associated with the risk 
of local failure. The NSBABP B-06 analyses showed high nuclear grade associated 
with increased risk for local recurrence.49 In the JCRT series, grade 3 tumors were 
associated with higher percentages of local failure.50 The Marseille Risk Factor study 
showed mononuclear cell reaction, a marker of aggressive tumor growth, and high 
histologic grade were predictors of local failure.11 The need for more accessible and 
easily reproducible measures of biological aggressiveness, such as DNA-FC analyses 
or measurements of growth fractions with monoclonal antibody techniques, is 
proposed. To date, only microscopic examination of tumor specimens can be used to 
assess risk of local failure secondary to tumor aggressiveness in conservatively treated 
patients.11 

PROGNOSIS FOLLOWING LOCAL RECURRENCE 
Prognosis following local recurrence for patients treated with conservative 
therapy differs from that of patients treated with mastectomy. 33-50% of patients 
experiencing chest wall recurrence after mastectomy have concurrent distant metastases. 
In contrast 9-25% of patients experiencing local failure following conservative 
treatment have concurrent distant disease.16 Patients who recurred in the chest wall 
after mastectomy and subsequently received radiation therapy where followed by the 
Joint Center at Harvard. Five-year disease-free survival in this group was 30% and 
decreased to 7% at ten years.16 This trend is confirmed by several studies which report 
survival following chest wall recurrence in patients treated with primary mastectomy 
ranges from 21-36% at five years and 5-26% at ten years.5154 In contrast, various 
studies report five-year disease-free survival following local recurrence in 
conservatively treated patients between 59-84% and ten-year disease-free survival 
ranging from 50-65%.1215 Researchers at the Institut Gustave-Roussy and Princess 
Margaret Hospital failed to demonstrate any difference in overall survival between 
conservatively treated patients who experienced local failure and those who had never 
had a local recurrence.13-55 Table 4 provides survival data following local recurrence 
from several representative series. 
The optimal treatment for patients who experience local recurrence following 
conservative therapy is not yet known. Currently, most patients undergo salvage 
mastectomy, although in some cases further conservative treatment is employed.16 To 




To aid in the management of patients experiencing local recurrence after 
conservative therapy, efforts have been made to find reliable predictors of prognosis 
following failure. Currently available prognostic indicators are limited to clinical 
observations. Those most consistently reported are time to recurrence, extent and site 
of recurrence and histology of recurrence. 
In the Yale series, patients recurring four or more years after primary treatment 
had a significantly better prognosis than patients recurring sooner.20 Similarly, patients 
treated in the Marseille series were found to have a favorable prognosis (84% survival 
at five years) if they recurred five or more years after primary treatment.41 At the 
Institut Curie, recurrences occurring within three years after primary therapy were more 
often associated with concurrent nodal involvement and distant metastases and, as a 
result, poorer prognosis.20 The University of Pennsylvania series demonstrated a 
statistically insignificant trend towards poorer prognosis among early recurrences.15 
The JCRT failed to show any difference in survival among patients who recurred after 
two or more years compared to those recurring in less than two years.16 
Various measures assessing qualitative features of locally recurrent tumors have 
been predictive.15-16-20'41 Site and extent of local recurrence was predictive in the Yale 
series.20 Localized tumors, recurring elsewhere in the breast and measuring less than 3 
cm, were associated with a better prognosis. Similar findings have been reported by 
the University of Pennsylvania, Marseille and Gustave-Roussy.1315 41 Others have 
failed to demonstrate the prognostic value of these indicators.16 
13 

Examination of histologic features of recurrent tumors has not been uniformly 
helpful in predicting outcome. In the JCRT series, patients with purely or 
predominantly non-invasive recurrent tumors suffered no further recurrences, whereas, 
38% of patients with predominantly infiltrating tumors, experienced some further 
recurrence.16 Histology of the recurrent tumor, assessed somewhat differently, was 
not prognostic in the Yale series.20 
PROGNOSTIC INDICA TORS USED FOR PRIMAR Y BREAST CANCER 
At best, currently available data provides a number of clinical observations 
which can be associated with prognosis following local recurrence in the conservatively 
treated patient. Histologic features of the recurrent tumor are the only objective 
measures available, but data examining this potential predictor is scarce, inconclusive 
and hindered by potential problems of reproducibility. In contrast, prognosis for 
patients with primary breast cancer has been successfully predicted using a number of 
quantitative as well as qualitative factors. 
The Surveillance, Epidemiology and End Results (SEER) program of the 
National Cancer Institute has followed 24,740 breast cancer patients through tumor 
registries in five states.56 The results of this study indicate size of primary and lymph 
node status are independent but additive prognostic indicators for primary breast 
cancer. As tumor size increases, survival decreases regardless of nodal status. 
Likewise, as nodal involvement increases, survival status decreases regardless of tumor 
size. Patients with primaries less than 2 cm in diameter and negative lymph nodes have 
the most favorable prognosis with 96.3% five-year survival whereas patients with 
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primaries larger than 5 cm and positive axillary nodes have a survival at five years of 
only 45.5%. 
In addition to clinical measures of prognosis, several quantitative measures have 
proven to be valuable indicators of prognosis in primary breast cancer. Steroid 
hormone receptor status has well established independent predictive value.57 In 
patients with negative lymph nodes, positive estrogen receptor status is associated with 
a better overall and disease-free survival. For patients with positive nodal involvement 
progesterone receptor status is a strong prognosticator.58 In this case, lymph node¬ 
positive patients with positive progesterone receptor status have a better disease-free 
survival than their progesterone receptor negative counterparts. 
Currently evolving quantitative prognostic indicators for primary breast cancer 
include measures of DNA content and cellular proliferation, obtained using techniques 
of DNA-FC.27 Overall, tumors with DNA values within the limits of normal tissue 
correlate with favorable prognosis while tumors with high proliferative indices are 
associated with poor outcome.2126-28'30 
TECHNIQUES OF CELL ANAL YSIS USING DNA FLOW CYTOMETR Y 
While tumor cell proliferation can be measured by both the histologically 
derived mitotic index and the autoradiographically derived thymidine labeling index, the 
technique of DNA-FC provides rapid measurement of cell proliferation without the 
constraints of fresh tissue or labor intensive histologic analyses. In addition, measures 
of DNA content are concurrently obtained with DNA-FC analysis. Thus, DNA-FC 
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analysis of fresh or archival tumor cells allows direct measurement of DNA content 
(DNA-ploidy) and indirect measurement of tumor cell proliferation (S-phase fraction, 
SPF). When the measured DNA content of tumor cells is equal to that found in normal 
cells the tumor is defined as DNA-diploid. If the DNA content is either greater or less 
than normal, the tumor is defined as DNA-aneuploid. 
Hedley developed the technique for analyzing paraffin-embedded archival tissue 
with DNA-FC after observing the impressive degree of cellular preservation in paraffin- 
embedded tissue slices which were dewaxed and rehydrated.59 Once archival tumors 
cells are rehydrated, they are processed in a manner similar to that previously 
established for cytometric analysis of fresh tissue. Intact tumor cells are treated with a 
digestive enzyme, such as trypsin or pepsin, with subsequent tumor lysis. The freed 
cellular nuclei are then tagged with an appropriate DNA fluorochrome and run through 
the DNA flow cytometer. 
The flow cytometer has four components: a light source, usually a laser, a 
sample chamber and optical assembly, a set of associated electronics that convert light 
impulses to digital signals and a computer system that controls instrument operations, 
collects data and performs analytical routines.60 Once a cell sample is prepared, it is 
added to the sample chamber and at a rate of approximately 10,000 cells per second, 
passes single file past the light source. As cells pass the laser, light is scattered in all 
directions. Light which is deflected forward is referred to as forward angle light scatter 
(FALS) and is directly proportional to the size of the passing particle, assuming the 
particle is a homogeneous sphere. Light which is orthogonally deflected is referred to 
as 90 degree light scatter (90°LS). It is reflected from internal cellular structures and is 

indicative of cell granularity. Fluorescent emissions from DNA specific probes excite 
the system’s lasers and generate histograms from which the DNA content of resting and 
dividing cell populations is determined. The DNA flow cytometric histogram from a 
normal cell population will contain a single G0/G1 peak representing most of the 
sample’s cells in the resting phase of the cell cycle. Smaller peaks will be generated by 
cells in the proliferative G2/M and S-phases. 
A cell population is defined as DNA-aneuploid if it has two or more G0/G1 
peaks with the second being at least 10% of the first.61 DNA index is the calculated 
ratio of the abnormal G0/G1 peak to the normal G0/G1 peak. Cell cycle analysis 
computer programs divide DNA histograms into their constituent parts of G0/G1, 
G2/M and SPF by assessing the relative distribution of DNA. Representative DNA- 
diploid and DNA-aneuploid histograms appear in figures 1 and 2 respectively. 
THE USE OF DNA FLOW CYTOMETRY AS A PROGNOSTIC INDICATOR 
FOLLOWING LOCAL RECURRENCE 
Measures of DNA content and cellular proliferation are valuable prognostic 
indicators for a number of solid and non-solid tumors.62 Methods have been 
successfully developed to apply DNA-FC analysis on paraffin-embedded archival 
tissue. The reproducibility and correlation between data derived from fresh and 
archival tissue has been verified by Hedley and others.59-63 68 Applying this 
technology to the readily available archival tissue obtained from patients who 
experienced local recurrence in the Yale series should provide an indication of the 
prognostic value this measure holds for this population. 
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Methods and Materials 
PA TIENTS 
433 patients with primary clinical stage I and stage II breast cancer were treated 
with conservational surgery and primary irradiation at the Yale-New Haven Hospital 
between January 1962 and December 1984. Clinical staging was in accordance with 
the guidelines of the American Joint Committee/ Union Internationale Contre Le 
Cancer. Conservational surgery involved excisional biopsy of the breast lesion with no 
specific attempt made to obtain microscopically free surgical margins, although the 
surgical specimen generally contained a rim of normal breast tissue around the tumor. 
Axillary dissection was not routinely performed. Most patients did not receive adjuvant 
systemic therapy although multi-agent chemotherapy or hormonal therapy was used in 
some patients with pathologically positive nodes. 
Radiation therapy was delivered using 4-6 MeV linear accelerators with 
tangential fields directed at the breast with an electron boost to the tumor bed to a total 
median dose of 6400 cGy. Radiation was delivered in 200 centigrade per day 
fractions. Wedges were routinely employed to optimize dose homogeneity throughout 
the breast tissue. 
The regional nodes were treated in the majority of patients. In patients not 
undergoing axillary dissection, the internal mammary, supraclavicular and axillary 
nodes were irradiated. Internal mammary nodes were irradiated with alternating 
photons and 13 MeV electrons with a separate field to a total median dose of 4600 cGy 
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specified at a depth of 3 cm. Occasionally the internal mammary nodes were included 
in the tangential fields. Supraclavicular and axillary nodes were treated with a separate 
half-blocked anterior field angled 10-15° off of the spinal cord. The field extended 
medially from the midline angled off the spinal cord and cleared the entire axillary 
contents laterally. 
In patients undergoing axillary dissection, the internal mammary chains and 
breast were treated as described above. The supraclavicular field, however extended 
only from the midline to approximately the medial border of the humeral head laterally, 
thus sparing the lower axillary contents in both node positive and node negative 
patients. Radiation treatment was delivered over a six to seven week period. Figure 3 
schematically represents these treatment policies. 
Patients were seen in follow-up by both the radiation oncologist and referring 
surgeon at three to six month intervals. Routine mammograms and chest X-rays were 
performed annually. Follow-up liver scans and bone scans were not performed unless 
clinically indicated. Disease and survival status for each patient is routinely updated 
with documented follow-up visits, correspondence with the patient and her surgeon or 
internist and through data available from state tumor registries. 
Charts were retrospectively reviewed in an effort to document all patients 
experiencing local recurrence. 50 patients experienced recurrent tumor in the 
conservatively treated breast prior to June 1990. An effort was made to obtain tissue 
samples from the recurrent breast tumors of these patients. Tissue could be retrieved 
for 76% of the recurrent tumors. 
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DMA FLOW CYTOMETRY 
DNA-FC analysis was carried out on all available tissue samples. Cell 
preparation was carried out as follows. 50 pm sections were obtained from each 
paraffin-embedded sample. An additional 6 pm cut was made from each section and a 
slide prepared to verify the presence of tumor cells in each section. Sections were 
deparaffinized with Americlear solution, followed by stepwise hydration in ethanol 
(100%, 95%, 70%,50%) and distilled water. Cells were then treated with pepsin and 
lysed. Nuclear material was tagged with propidium iodide and analyzed with an Epics 
Profile flow cytometer (Coulter Electronics Inc.) using 488 nm excitation. Both 
forward and 90 degree light scatter gates were used to exclude debris signals. DNA 
index and cell cycle distribution were calculated using the Modfit software program. 
The mean coefficient of variation for the entire sample was 5.6 (median 5.2). 
ST A TISTICAL ANAL YSIS 
Statistical analyses were performed employing the PRODAS statistical package from 
Conceptual Software Inc. on a Zenith 386 IBM compatible computer. The significance 
of survival differences between patient groups was calculated according to the Cox Life 
Table and Survival Analysis Model. The Cox Life Table Regression Model was 




PA TIENT POPULA TION 
As of January 1990, 433 patients, with a minimum follow-up of five years and 
a median follow-up of 8.21 years, have received conservative treatment at the Yale- 
New Haven Hospital. Characteristics of the treated population appear in table 5. The 
median age of treated patients is 55.0 years (range, 20-89 years). 70% were treated for 
clinical stage I breast cancer. 43% underwent axillary dissection. 9% received 
adjuvant hormonal therapy and 12% received adjuvant chemotherapy. The overall five- 
year actuarial survival rate for the population is 0.86 ± 0.02, the actuarial five-year 
disease-free survival rate is 0.82 ± 0.02. 
PATIENTS WITH LOCAL RECURRENCE 
Patient status, as of January 1990, appears in table 6. 82% of patients in the 
entire population remain alive. 50 patients have experienced local failure with a five- 
year actuarial breast recurrence rate of 0.08 ± .02. 44 of the recurrences were confined 
to the breast, 6 patients had coincident distant disease. Follow-up is available for a 
median of 5.06 years following recurrence. 
Flow data was obtained from 100% of available tissue samples. Recurrent 
tumor tissue was available for 38 patients (76%). Patients for whom tumor tissue is 
available do not differ significantly from the total recurrent population in terms of age, 
original clinical stage, original nodal status, mode of recurrence detection, interval to 
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recurrence, site of recurrence, extent of recurrence, adjuvant therapy, salvage therapy 
and disease status (table 7). 
Figures 4 and 5 depict actuarial curves of overall and disease-free survival for 
all patients experiencing local recurrence and for patients with available flow data. 
Median follow-up post-recurrence for patients with flow data is 5.8 years. For all 
recurrences the Five-year actuarial survival post-recurrence is 59% and five-year 
actuarial disease-free survival post-recurrence is 65%. For patients with available flow 
data, overall actuarial survival Five-years following recurrence is 48%. Actuarial 
disease-free survival for patients with available flow data is 58% at Five-years following 
recurrence. 
Univariate analysis shows extent of recurrence and time to recurrence are 
predictive for Five-year disease-free survival among the patients with available recurrent 
flow data (p = 0.000 and 0.007 respectively). Extent of recurrence predicts overall 
survival in this group (p = 0.005), while time to recurrence approaches statistical 
significance (p = 0.06). 
DNA-PLOIDY 
Most recurrent tumors (62.8%) were DNA-diploid. Univariate analysis, using 
the Cox Life Table Regression Model, shows DNA-ploidy is predictive of overall 
survival and disease-free survival Five-years after local failure (p=0.015 and p=0.028, 
respectively). Overall actuarial survival, calculated according to the Cox Life Table and 
Survival Model, at five-years post recurrence is 63.0% in patients with DNA-diploid 
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tumors and 14.9% in patients with DNA-aneuploid tumors. Actuarial curves depicting 
overall survival appear in figure 6. DNA-ploidy, calculated by Chi-square analysis, is 
positively correlated with distant disease progression (p < 0.05). 46% of patients with 
DNA-aneuploid tumors remain distant disease-free, whereas, 76% of patient with 
DNA-diploid tumors are free of distant disease progression (table 8). 
S-PHASE FRACTION 
The median SPF for the sample was 13.8. An SPF value of less than to 12 was 
used to define tumors with a low proliferative index. 35% of patients had a tumors 
with a low proliferative index. When subjected to univariate analysis, favorable 
proliferative index was found to be predictive of overall survival at five-years post 
recurrence (p=0.01) as well as disease-free survival at five-years post recurrence (p = 
0.0002). Overall, actuarial survival five-years post recurrence is 82.6% in patients 
with low SPF tumors and 24.0% in patients with high SPF tumors. Actuarial disease- 
free survival five-years post recurrence is 100% in patients with low SPF tumors and 
32.1% in patients with high SPF tumors. Actuarial curves depicting this data are 
presented in Figures 7 and 8. SPF is positively correlated with distant disease 
progression, (p <0.01). 56% of patients with high SPF tumors have had distant 
disease progression while, 100% of the patients with low SPF tumors remain distant 
disease free (table 8). 
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COMBINED DNA-PLOIDY AND S-PHASE FRACTION 
The results of the separate analyses of patients according to DNA-ploidy and S- 
phase were combined to create classifications of tumors with favorable and unfavorable 
flow profiles. Tumors with a favorable flow profile are defined as DNA-diploid with a 
SPF less than 12. Those with an unfavorable flow profile are defined as DNA- 
aneuploid or DNA-diploid with an SPF greater than 12. 13 patients (30%) had 
favorable flow profiles. Univariate analysis shows favorable flow profile is predictive 
of overall survival five-years post recurrence (p=0.03) and disease-free survival five- 
years post recurrence (p=0.00005). Overall actuarial survival five-years after 
recurrence is 60% for patients with a favorable flow profile and 24% for patients with 
an unfavorable flow profile (figure 9). Actuarial disease-free survival five-years after 
recurrence is 100% for patients with a favorable flow profile and 36% for patients with 
an unfavorable flow profile (figure 10). Distant disease progression is positively 
correlated with flow profile (p < 0.01). 52% of patients with unfavorable flow profiles 
had distant disease progression, whereas, 100% of patients with favorable flow 
profiles remain free of distant disease (table 8). 
The distribution of previously established post-recurrence prognostic indicators 
among patients with favorable and unfavorable flow profiles appears in table 9. The 
clinical predictors of prognosis, interval to recurrence, site of recurrence and extent of 




Local recurrence in the conservatively treated patient is associated with a 
prognosis more favorable than that of a patient who has suffered local failure following 
primary treatment with mastectomy. Following salvage mastectomy, approximately 
50% of these patients will remain disease-free and 50% will succumb to progressive 
disease. Measures of recurrent tumor DNA content and proliferative index obtained 
through DNA-FC appear to be predictive indicators in this population of patients. 
When compared to patients with DNA-diploid recurrences, patients with DNA- 
aneuploid tumors have shorter overall and disease-free survival. This parameter has 
not been systematically measured in patients experiencing local failure following 
conservative treatment. Its prognostic value for primary breast cancer is widely 
reported.23'26 28’30-65 Beerman performed DNA-FC on fresh and archival tissue from 
690 patients with stage I-III breast cancer followed for a median of seven years and 
observed that DNA-aneuploidy was associated with shortened overall and disease-free 
survival.30 Coulson looked at 74 patients with a median follow-up of three years and 
found 92% of deaths occurring within three years were in patients with DNA-aneuploid 
tumors.26 Others have failed to demonstrate the prognostic value of DNA-FC when 
measuring DNA-ploidy alone.29 69 Toikkanen’s retrospective examination of tissue 
from 115 stage I-II breast cancer patients with a median follow-up of twenty-seven 
years failed to demonstrate any influence on survival with respect to DNA-ploidy.29 
Similarly, Rofagha’s examination of archival tissue from 165 patients with node¬ 
negative breast adenocarcinoma, followed for a median of eight years, did not show 
prognostic significance for measures of DNA ploidy. 69 
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Measures of S-phase fraction alone were highly significant predictors of overall 
and disease-free survival. Using the institutionally accepted cut-off of 12%, patients 
with low SPF had longer overall and disease-free survival. S-phase fraction has not 
been previously examined as a prognostic indicator following local recurrence in 
conservatively treated breast cancer but its utility as a prognostic indicator in primary 
breast cancer is well documented 21,23,65 Using 9% as a cut off for low SPF, 
Hatschek measured SPF in the primary tumors of 15 patients who experienced local 
failure. The patients’ initial staging and mode of treatment were not reported. High 
SPF was associated with an increased, but not statistically significant, risk of 
recurrence but did significantly correlate with length of survival following 
dissemination of disease.24 
DNA-ploidy and S-phase fraction both independently predict outcome 
following local recurrence. Information derived from these two parameters was 
combined to assign patients to favorable and unfavorable groups. Patients with 
’’favorable” flow profiles (DNA-diploid, SPF < 12) had significantly longer overall and 
disease-free survival. This is in agreement with studies in patients with primary breast 
cancer, which have assigned patients to prognostic groups by combining measures of 
DNA-ploidy and SPF.22 23 Clark’s examination of breast tissue from 345 node¬ 
negative patients with a median follow-up of 4.9 years showed that overall and disease- 
free survival was longest in patients with DNA-diploid, low SPF tumors.22 
Kallioniemi applied a prognostic index which includes DNA index and S-phase fraction 




In order to apply data derived from DNA-FC to clinical practice, the reliability 
of these measures must be considered. The established ’’gold-standard” for 
measurement of cell proliferative indices is tritiated thymidine labeling (TLI). This 
autoradiographic technique cannot be practically applied on a large scale because it is 
time consuming, expensive and requires fresh tissue. Nonetheless, its value as a 
powerful independent prognostic indicator in primary breast cancer is strongly 
supported in the literature.27 DNA-FC provides information on both DNA content and 
proliferative index and offers the advantage of rapid tissue analysis which can be 
performed on fresh or archival tissue. Costa and McDivitt report a positive correlation 
between S-phase values obtained by DNA flow cytometry and those obtained by 
tritiated thymidine labeling.67 70 Kallioniemi’s comparison of fresh and paraffin- 
embedded tumors showed S-phase fractions from both tissue types were positively 
correlated.64 
Technical difficulties associated with flow cytometric analysis of paraffin- 
embedded tissue raise concern about the accuracy of its determinations. Analysis of 
paraffin-embedded tumors is usually associated with a larger coefficient of variation 
representing larger proportions of cellular debris in the tissue sample. This raises the 
concern that some near DNA-diploid tumors are misclassified as DNA-diploid. Hedley 
looked at 233 frozen tissue samples and compared them to 280 paraffin-embedded 
breast tumors with similar pathological staging and found the paraffin samples had a 
higher proportion of tissues with a DNA index of 1.0 (DNA-diploid). Yet, his 
comparison of 24 frozen and paraffin-embedded samples from the same tumor yielded 
identical proportions of near DNA-diploid tumors.65 
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The reliability of SPF measures derived from paraffin-embedded tissue has also 
been called into question.64 In the case of DNA-aneuploid tumors, overlapping cell- 
cycle distributions create technical difficulties in determining S-phase fraction which, in 
contrast, is usually readily evaluable in DNA-diploid tumors. However, in DNA- 
diploid tumors interpretation of SPF is difficult because the cell-cycle distribution 
represents both tumor and non-tumor cells. Kallioniemi demonstrated greater 
intratumor variation in SPF measures derived from DNA-diploid tumors and concludes 
this results from cytometrically indistinguishable populations of tumor and non-tumor 
cells in a DNA-diploid tissue sample.64 He notes, however, that the extent of this 
problem can be reduced by carefully selecting for analysis only those tissue sections 
which contain large numbers of tumor cells. Despite these potential technical 
limitations, DNA-ploidy and S-phase fraction determinations have been consistently 
correlated with outcome in primary breast cancer. 
The implications of the data presented in this study rest in its potential role as a 
guide for the clinical management of patients experiencing local recurrence following 
conservative treatment for early stage breast cancer. Unlike primary breast cancer, for 
which the well defined prognostic indicators of stage, lymph node and receptor status 
are used to guide treatment, few prognostic indicators are available to help guide the 
management of patients experiencing local failure following conservative therapy. 
Axillary exploration at the time of recurrence is of questionable value. Most patients 
undergoing conservative treatment undergo axillary dissection and irradiation at the time 
of primary treatment. This makes re-exploration at the time of recurrence a technically 
difficult, low yield procedure. Although retrieval of a positive lymph node may 
influence decisions regarding adjuvant systemic therapy, the conclusions derived from 
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an absence of involved nodes must remain equivocal, due to the necessarily small 
sample likely to be retrieved from a previously dissected axilla. 
The prognostic significance of hormone receptor status in this patient population 
remains undetermined. Preliminary analysis of receptor status in the Yale series 
suggests patients with recurrent tumors which are estrogen receptor-negative have 
poorer survival than patients with estrogen receptor-positive tumors.20 Unfortunately 
this data is available for only 33% of the patients experiencing local recurrence. 
Determination of receptor status by immunohistochemical staining of paraffin- 
embedded blocks, obtained from the majority of patients experiencing local failure in 
our series, is currently underway. 
Clinical and pathological variables, including time to recurrence, extent and 
location of recurrence and tumor histology, have been shown to be prognostically 
significant. Adapting these variables for use as guides for the clinical management of 
patients following local failure is hampered by their heavy reliance on observer 
judgment and resulting problems of reproducibility due to inter-observer variability. In 
contrast, DNA-FC analysis provides readily reproducible quantitative measures which, 
in our series, were positively correlated with these previously established clinical 
prognostic factors. 
The low overall incidence of local recurrence following conservative treatment 
for early stage breast cancer results in relatively small numbers of patients available for 
study. The accumulation of larger samples with longer follow-up will be necessary to 
firmly establish the prognostic significance of DNA-FC analysis for this population. 
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When this is achieved, these prognostic factors can be used to design the randomized 
prospective clinical trials which will be necessary to determine optimal salvage 
treatment and appropriate adjuvant systemic therapy for patients experiencing local 
recurrence following conservative treatment. 
In summary, DNA flow cytometric measurements of DNA-ploidy and S-phase 
fraction in local recurrent tumor tissue may help predict overall and disease-free 
survival following local failure in conservatively treated stage I-II breast cancer 
patients. In our sample patients with DNA-diploid, low S-phase tumors had an 
excellent prognosis. With further verification of these findings by others with similar 
patient populations, the application of this data to the clinical management of patients 
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Local Recurrence Rates in Conservatively Treated Early Stage Breast Cancer 
Series Subjects Follow-up Breast 
Recurrence Rate 
GUSTAVE-ROUSSY13 436 5.0 years 7% at five years 
MDAH 10 536 5.3 years 9% at five years 
JCRT 40 607 6.3 years 9% at five years 
YALE 20 433 8.2 years 8% at five years 
MARSEILLE 9 1593 11 years 7% at five years 

Table 4 










Yale 20 50 5.0 years 59% at five years 
JCRT 16 90 2.8 years 69% at eight years 
Univ. of Pennsylvania* 15 65 1.6 years 84% at five years 
Marseille 14 178 not reported 70% at five years 




Patient Population Characteristics 
N=433 
Characteristic Frequency Percentage 
AGE 
<50 years 159 37 
>50 years 274 63 
CLINICAL STAGE 
Stage I 301 70 
Stage II 132 30 
PATHOLOGICAL NODAL STATUS 
Node-negative 128 30 
Node-positive 57 13 
No axilllary dissection 248 57 
ADJUVANT THERAPY 
Chemotherapy 
No 379 87 
Yes 54 12 
Hormonal Therapy 
No 393 91 
Yes 40 9 
*Mean age is 54.0 years (Median 55.0 years). 




Patient Status as of January 1990 
N=433 
Status Frequency Percentage 
ALIVE 356 82 
DEAD 77 18 
FAILURE 
Treated breast alone 44 10 
Treated breast with distant metastases 6 13 
Lymph nodes 12 11 




Comparison of Characteristics of All Patients Experiencing Local 
Recurrence and Those with Flow Data Available 
Characteristic All Recurrences Recurrences with 
N=50 Flow Data 
N = 38 
frequency % frequency % P 
AGE AT DIAGNOSIS 
<50 years 25 50 14 37 NS 
>50 years 25 50 24 63 
CONICAL STAGE 
Stage I 37 74 28 74 NS 
Stage 13 13 26 10 26 
ORIGINAL PATHOLOGICAL NODE STATUS 
Node-negative 13 26 8 21 NS 
Node-positive 9 18 7 18 
Unknown 28 56 23 61 
MODE OF DETECTION 
Physical exam only 19 38 16 42 NS 
Mammography only 14 28 10 26 
Physical exam and mammography 14 28 10 26 
Physical exam, mammography negative 3 6 2 5 
SALVAGE THERAPY 
Modified radical mastectomy 21 42 15 39 NS 
Simple mastectomy 18 36 14 37 
Lumpectomy 7 14 4 10 
Biopsy 4 8 4 10 
INTERVAL TO RECURRENCE 
< 4 years 24 48 19 50 NS 
> 4 years 26 52 19 50 
SITE OF RECURRENCE 
Same site 36 72 28 74 NS 
Elsewhere 14 28 10 26 
EXTENT OF RECURRENCE 
Localized 38 76 28 74 NS 
Diffuse 12 24 10 26 
ADJUVANT THERAPY 
Chemotherapy 15 30 11 29 NS 
Hormonal therapy 8 16 8 21 
None 27 54 19 50 
DISEASE STATUS 
Alive, No Evidence of Disease 27 54 17 44 NS 
Alive, with Disease 5 10 5 13 
Dead, No Evidence of Disease 2 4 2 5 




Frequency of Distant Disease Progression by Flow Parameters at Recurrence 
N=38 
Flow Parameters No Distant Disease Distant Disease 
Progression 
frequency % frequency % P 
DNA-PLOIDY 
DNA-Diploid 19 76 6 24 p < 0.05 
DNA-Aneuploid 6 46 7 54 
S-PHASE FRACTION 
SPF < 12 15 100 0 0 p < 0.01 
SPF > 12 10 43 13 57 
FLOW PROFILE 
Favorable (D, <12) 13 100 0 0 p < 0.01 




Distribution of Post-recurrence Prognostic Indicators Among Patients with Favorable 
and Unfavorable Flow Data* 
N=38 





N = 24 
frequency % frequency % P 
INTERVAL TO RECURRENCE 
< 4 years 3 21 16 67 p < 0.01 
> 4 years 11 79 8 33 
SITE OF RECURRENCE 
Same site 7 50 21 87 p < 0.05 
Elsewhere 7 50 3 13 
EXTENT OF RECURRENCE 
Localized 14 100 14 58 p < 0.01 
Diffuse 0 0 10 42 
* Favorable Flow Profile = Diploid with SPF £ 12 
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Schematic Representation of Radiation Treatment Policy 











All Recurrences vs. Recurrences with Flow Data* 


















All Recurrences vs. Recurrences with Flow Data* 











By DNA-ploidy at First Breast Recurrence* 











By SPF at First Breast Recurrence* 


















By SPF at First Breast Recurrence* 











By Flow Profile at First Breast Recurrence* 


















By Flow Profile at First Breast Recurrence* 
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